Thomas Wegman

Strong 2Q for ageless BioSpecifics Technologies

Significant progress in its clinical-development programs – and a chunky opt-in payment from a major international partner – won’t affect BioSpecifics Technologies Corp.’s financial fortunes until the third quarter, but the spry old timer of Long Island biopharmaceuticals is already riding high. The Lynbrook-based, circa-1957 “specialty pharmaceuticals corporation” – which produces collagenase-based therapies for Peyronie’s disease, which causes the penis to curve, sometimes painfully, during an erection – on Tuesday reported strong financial results for…


Almost 60 years later, still very much a startup

By GREGORY ZELLER // “Innovative” is often associated with “new,” but when it comes to Long Island’s innovation economy, the region’s oldest biopharmaceutical company is leading the pack. With a five-person staff and a market cap over $300 million, Lynbrook’s BioSpecifics Technologies Corp. is one lean, mean biotech machine – and the most profitable days for the firm, which launched in 1957 among the nation’s first batch of biotech startups, may lie ahead. Consider the…